<DOC>
	<DOC>NCT01843361</DOC>
	<brief_summary>The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.</brief_summary>
	<brief_title>Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>acute ischemic stroke admittance to stroke unit clopidogrel medication no consent prior bleeding disorders severe liver disorders current gastrointestinal disorders congestive heart failure lifethreatening malignancies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Aggregometry</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Platelet function tests</keyword>
</DOC>